KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2025)

AbCellera Biologics' Share-based Compensation history spans 6 years, with the latest figure at $12.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 15.25% year-over-year to $12.9 million, compared with a TTM value of $55.8 million through Dec 2025, down 17.44%, and an annual FY2025 reading of $55.8 million, down 17.44% over the prior year.
  • Share-based Compensation for Q4 2025 was $12.9 million at AbCellera Biologics, down from $13.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $17.8 million in Q2 2024, with the low at $5.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $13.4 million, with a median of $14.1 million recorded in 2025.
  • Year-over-year, Share-based Compensation surged 1298.18% in 2021 and then fell 20.1% in 2025.
  • Tracing ABCL's Share-based Compensation over 5 years: stood at $9.0 million in 2021, then surged by 47.41% to $13.3 million in 2022, then grew by 23.46% to $16.4 million in 2023, then dropped by 7.43% to $15.2 million in 2024, then decreased by 15.25% to $12.9 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Share-based Compensation are $12.9 million (Q4 2025), $13.9 million (Q3 2025), and $14.2 million (Q2 2025).